Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 489 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Blurred Vision
BMJ 368:m569, Zhou, S.,et al, 2020

Ischemic Optic Neuropathies
NEJM 372:2428-2436, Biousse, V. & Newman, N.J., 2015

Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008

Deterioration of Giant Cell Arteritis With Corticosteroid Therapy
Arch Neurol 57:581-584, Staunton,H.,et al, 2000

Isolated Angiitis of the Central Nervous System:Lack of Inflammation after Long-Term Treatment
Neurol 52:196-199, Reimer,G.,et al, 1999

Ergotamine Headache Mistaken for Temporal Arteritis
Ann Neurol 28:396, Winterkorn,J.M.S.,et al, 1990

New-Onset Diplopia and Headache in a Patient with Metastatic Breast Cancer
Neurol 100:927-931, Rizzo,S.A.,et al, 2023

Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011

Hemorrhagic Manifestations of Reversible Cerebral Vasoconstriction Syndrome: Frequency, Features, and Risk Factors
Stroke 41:2505-2511, 2455, Ducros,A.,et al, 2010

Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009

Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009

Narrative Review: Reversible Cerebral Vasoconstriction Syndromes
Ann Intern Med 146:34-44, Calabrese,L.H.,et al, 2007

Diffuse Cerebral Vasoconstriction (Call-Fleming Syndrome) and Stroke Associated with Antidepressants
Neurol 67:159-160, Noskin,O.,et al, 2006

Vasculitic Mononeuritis Multiplex Induced by Valcyclovir
Neurol 62:1906-1907, Pary,L.F.,et al, 2004

Stroke Associated with Sympathomimetics Contained in Over-the Counter Cough and Cold Drugs
Stroke 34:1667-1673, Cantu,C.,et al, 2003

Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids
NEJM 343:1833-1838,1886, Haller,C.A. & Benowitz,N.L., 2000

Diffuse Cerebral Vasculitis with Normal Results on Brain MR Imaging
AJR 173:1494-1496, Imbesi,S.G., 1999

Cerebral Vasculitis During FK 506 Treatment in a Liver Transplant Patient
Neurol 50:1154-1157, Pizzolato,G.P.,et al, 1998

Large Cerebral Infarction During Praziquantel Therapy in Neurocysticercosis
Stroke 28:211-213, Bang,O.Y.,et al, 1997

Ginseng-Associated Cerebral Arteritis
Neurol 45:829-830, Ryu,S.J.&Chien,Y.Y., 1995

Adverse Drug Effects Attributed to Phenylpropanolamine:A Review of 142 Case Reports
Am J Med 89:195-208, Lake,C.R.,et al, 1990

Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025

Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025

Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025

Risk of Dementia in Individuals with Emergency Department Visits or Hospitalizations Due to Cannabis
JAMA Neurol 82:570-579, Myran,D.T.,et al, 2025

AAV9-Mediated Gene Therapy for Infantile-Onset Pompes Disease
NEJM 392:2438-2446, 2477, Ma,X.,et al, 2025

Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024

Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Autoimmune Encephalitis Misdiagnosis in Adults
JAMA Neurol 80:30-39, Flanagan,E.P.,et al, 2023

Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023

Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022

Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022

A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022

Chorioretinopathy After Corticosteroid Treatment for Optic Neuritis
Neurol 96:e305-e306, Ling, J. and Micieli, J.A., 2021

Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021

A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021

Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021

Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021

Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021

Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021

Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020



Showing articles 0 to 50 of 489 Next >>